“…The results of the meta-analysis showed that the treatment effect and safety of both transanal endoscopic microsurgery and radical surgery in distant metastasis (RR, 0.59 (0.34, 1.02), P > 0.05), overall recurrence (RR, 1.49 (0.96, 2.31), P > 0.05), disease-specific-survival (RR, 0.74 (0.09, 1.57), P > 0.05), dehiscence of the sutureline or anastomosis leakage (RR, 0.57 (0.30, 1.06), P > 0.05), postoperative bleeding (RR, 0.47 (0.22, 0.99), P > 0.05), and pneumonia (RR, 0.37, (0.10, 1.40), P > 0.05) were not significantly different. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Metastasis is the main cause of death in patients with colorectal cancer (CRC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: nCT achieved similar pCR and downstaging rates with lower incidence of perioperative distant metastasis and preventive ileostomy compared with nCRT. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: While adjuvant endocrine therapy (ET) may decrease the mortality rate of estrogen receptor-positive (ER+) breast cancer (BC), the likelihood of relapse and metastasis due to ET resistance remains high. Cuproptosis is a recently discovered regulated cell death (RCD), whose role in tumors has yet to be elucidated. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OS was considerably lower for cohort A (20.1 months vs. 36.0 months; P = 0.0001) and was better for patients with ex19del, no brain metastasis, and low tumor mutation burden. At the time of progression, more mutations were found in cohort A, identifying off-target alterations more frequently, including TP53, RAS, and RB1. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Liver hepatocellular carcinoma (LIHC) is a highly malignant tumor with high metastasis and recurrence rates. Due to the relation between lipid metabolism and the tumor immune microenvironment is constantly being elucidated, this work is carried out to produce a new prognostic gene signature that incorporates immune profiles and lipid metabolism of LIHC patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Compared with TaTME, patients who underwent MiTME had no statistical difference in operation time (SMD -0.14; CI -0.31 to 0.33; I(2=)84.7%, P=0.116), estimated blood loss (SMD 0.05; CI -0.05 to 0.14; I(2=)48%, P=0.338), postoperative hospital stay (RR 0.08; CI -0.07 to 0.22; I(2=)0%, P=0.308), over complications (RR 0.98; CI 0.88 to 1.08; I(2=)25.4%, P=0.644), intraoperative complications (RR 0.94; CI 0.69 to 1.29; I(2=)31.1%, P=0.712), postoperative complications (RR 0.98; CI 0.87 to 1.11; I(2=)16.1%, P=0.789), anastomotic stenosis (RR 0.85; CI 0.73 to 0.98; I(2=)7.4%, P=0.564), wound infection (RR 1.08; CI 0.65 to 1.81; I(2=)1.9%, P=0.755), circumferential resection margin (RR 1.10; CI 0.91 to 1.34; I(2=)0%, P=0.322), distal resection margin (RR 1.49; CI 0.73 to 3.05; I(2=)0%, P=0.272), major low anterior resection syndrome (RR 0.93; CI 0.79 to 1.10; I(2=)0%, P=0.386), lymph node yield (SMD 0.06; CI -0.04 to 0.17; I(2=)39.6%, P=0.249), 2-year DFS rate (RR 0.99; CI 0.88 to 1.11; I(2=)0%, P = 0.816), 2-year OS rate (RR 1.00; CI 0.90 to 1.11; I(2=)0%, P = 0.969), distant metastasis rate (RR 0.47; CI 0.17 to 1.29; I(2=)0%, P = 0.143), and local recurrence rate (RR 1.49; CI 0.75 to 2.97; I(2=)0%, P = 0.250). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: FAT4 (FAT Atypical Cadherin 4) is a member of the cadherin-associated protein family, which has been shown to function as a tumor suppressor by inhibiting proliferation and metastasis. The Wnt/β-catenin pathway activation is highly associated with PD-L1-associated tumor immune escape. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Univariate Cox analysis of CD147 expression and clinical characteristics of HCC and multivariate Cox analysis of CD147 patterns and pathological tumor-node-metastasis stage showed significant differences (univariate Cox, P = 0.00013, HR: 1.424, 95%CI: 1.884 to 1.707 and P = 0.00066, HR: 1.376, 95%CI: 1.145 to 1.654, respectively; multivariate Cox, P = 0.00578, HR: 1.507, 95%CI: 1.126 to 2.018 and P = 0.00336, HR: 1.443, 95%CI: 1.129 to 1.844, respectively). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Small cell lung cancer (SCLC) is a highly malignant cancer characterized by metastasis and an extremely poor prognosis. Although combined chemoimmunotherapy improves the prognosis of extensive-stage (ES)-SCLC, the survival benefits remain limited. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…S100 calcium-binding proteins possess broad biological functions, such as cancer cell proliferation, apoptosis, tumor metastasis, and inflammation (Nat Rev Cancer 15:96–109, 2015). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Ultimately, the absence of distant metastasis M displayed a strong positive impact on CB far ahead of the tumor size T (standardized average estimate 0.88 vs. 0.4). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…With a 95% confidence interval, a pooled odd ratio (OR) was used to calculate the relationship between NOX4 expression patterns and cancer metastasis. There were 1060 tumor patients in all sixteen research that made up this meta-analysis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Hormone therapy was given as standard care in all trial arms, with local radiotherapy encouraged for newly diagnosed patients without distant metastasis. Randomisation was done using minimisation with a random element across seven stratification factors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Median Karnofsky performance status (KPS) was 90 (range 25/75% 80–100). 49.2% of patients had prior systemic therapy. Median metastasis volume was 10.58 cc (range 25/75% 3.7–25.54 cc). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The results of multivariable Cox model analysis showed that "personalized molecular P-TNM staging", micrometastasis in peripheral blood, pathological types of the tumor and mediastinal lymph node metastasis of the cancer were the most significant factors for predicting prognosis in the patients with locally advanced nonsmall lung cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the immunohistochemical expression of vascular endothelial growth factor (VEGF) family ligands (VEGF-A and VEGF-C) and receptors (VEGFR1, VEGFR2 and VEGFR3) in breast cancer and their associations with clinicopathological parameters, cancer subtypes/subgroups and patient outcome. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 gene status was significantly associated with distant tumor metastasis and stage (P = 0.028 and 0.025). HER2 protein overexpression as measured by IHC or HER2 gene amplification as measured by FISH was not associated with overall survival (OS) or disease-specific survival for the overall group of 1058 patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Multivariate analyses of our validation-cohort revealed that high SOX2 expression represents a major risk-factor for poor survival (HR = 3·19; 95%CI 1·74–5·84; p < 0·01) that is independent from metastasis and other known clinical risk-factors at the time of diagnosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Of these, 21 women (26%) had high EC-pY397-FAK expression that was associated with estrogen receptor positivity (71% vs 46%; P = .04), progesterone receptor positivity (67% vs 39%; P = .03), high Ki67 (86% vs 41%; P < .001), 4-immunohistochemically stained luminal-B (52% vs 8%; P < .001), higher tumor category (T3/T4 category: 90% vs 59%; P = .01), high lymph node category (N2-3 category: 43% vs 5%; P < .001), and high tumor node metastasis stage (IIIA-IIIC: 90% vs 66%; P = .03). Of 21 patients with high EC-pY397-FAK expression levels, none showed pathologic complete response, compared with 11 of 61 patients with low EC-pY397-FAK expression levels who showed pathologic complete response (odds ratio, 0.70; 95% CI, 0.61-0.82; P = .04). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso